RefeRences

1 Jemal A, siegel R, Xu J, Ward e. cancer statistics, 2010. CA Can J Clin. 2010; 60:277-300.

2 Leyden WA et al. J Natl Cancer Inst. 2005; 97(9):675-683.

3 Andrae B et al. J Natl Cancer Inst. 2008; 100(9):622-629.

4 saslow D et al. J Low Genit Tract Dis. 2012; 16(3):175-204.

5 The American congress of Obstetricians and Gynecologists. AcOG Practice Bulletin. clinical Management Guidelines for Obstetrician-Gynecologists: screening for cervical cancer. november 2012.

6 centers for Disease control and Prevention. Genital HPV Infection—fact sheet. www.cdc.gov/std/hpv/stdfact-hpv.htm. Accessed november 2012.

7 cuzick J et al. Int J Cancer, 2006; 119:1095-1101.

8 de sanjose s et al. Lancet Oncol. 2010; 11:1048-1056.

Learn More – An Online Educational Resource Designed for You

Nurse practitioners and physician assistants play a critical role in educating, screening and counseling patients about HPV and cervical cancer. To learn more about how you can empower your patients when it comes to knowing their cervical cancer risk and to obtain printable patient education materials, visit www.HPV16and18.com/NPPA.

www.HPV16and18.com/NPPA

Cervical Cancer Screening

educational Resources for nurse Practitioners and Physician Assistants

COBAS and LIFE NEEDS ANSWERS are trademarks of Roche. © 2012 Roche Diagnostics. All rights reserved. 472-52023-1112 Roche Diagnostics9115 Hague RoadIndianapolis, IN 46256

Patient Leaflet Know Your Risk for Cervical Cancer?

Patient Counseling HandoutsPre-Testing counseling Materials •EarlyDetection •WhatisHPV? •cobas® HPV Test •CervicalAnatomy •WhatisCervicalCancer? •KnowYourRisk

Post-Testing counseling Materials •Co-Testing(PapandHPVtest) •Colposcopy •WellnessExam •Resources&Checklists

Educational toolkit materials are available online and can be downloaded and printed for use in your practice:

new Guidelines and the Importance of cervical cancer screeningWithmorethan12,000womendiagnosedannuallywith invasive cervical cancer in the United States,1 the importance ofscreeningforhigh-riskHPVtypesthatcouldleadtocervicalcancer has been well established. The global impact of Pap cytology screening in women’s health cannot be understated. However,uptoone-thirdofcervicalcancersoccurinscreenedwomen with normal Pap results.2,3

InMarch2012,amultidisciplinarypartnershipbetween theAmericanCancerSociety,theAmericanSocietyforColposcopyandCervicalPathology,andtheAmerican Society for Clinical Pathology released updated cervical cancer screening guidelines.4 The recommendations state thathigh-riskHPVco-testingprovidesincreasedsensitivityfor detecting cervical abnormalities and changes, and is preferred to using Pap cytology alone.

InNovember2012,thenation’slargestOB-GYNorganization, theAmericanCongressofObstetriciansandGynecologists,separately published guidelines for cervical cancer screening that aligned with the recommendations of these groups.5

Ataglance,thenewACS/ASCCP/ASCPguidelinesformanaging women with normal Pap cytology results recommend:4

Addressing the educational needTo help address this information gap and provide resources to help you talk with your patients about cervical cancer screening, RocheDiagnosticshasdevelopedan

educational toolkit that you can access atwww.HPV16and18.com/NPPA.Thekit

includes information on the recent survey, as well as educational resources that can be used with patients to facilitate discussion before and after cervical cancer screening.

The toolkit also serves as an easy reference, as it provides information on current cervical cancer screening guidelines and the latest clinical information about HPV. It also includes

important facts about HPV genotyping, includingthehighest-riskgenotypes,HPV16andHPV18,whichareresponsibleforapproximatelytwo-thirdsofallcervical cancer cases.8

The new cervical cancer screening guidelines provide significant opportunities for you to intervene for patients at all levels of care—from educating women about HPV and cervical cancer risk factors to implementing the new screening recommendations aimed at early detection.

survey saysInAugust2012,RocheDiagnosticsconductedasurveyofnursepractitioners and physician assistants to understand their level of awareness of the new cervical cancer screening guidelines and learn more about their screening practices. Findings showed that, while a majority of the surveyed nurse practitioners and physician assistants are aware that new cervical cancer screeningguidelineshavebeenissued,confusionexists on the specific recommendations.

Accordingtothesurvey,awarenessofcritical risk factors contributing to cervical cancerislow,withonly50%ofsurveyrespondents correctly identifying that over 75%ofwomenwillbeinfectedwithHPVat some point during their lives.6Addition-ally,lessthanone-in-fivesurveyedwereaware that cytology alone can miss approximately50%ofcervicalpre-cancer.7 Fourteen percent of nurse practitioners and physician assistants report using cytology alone for cervical cancer screening withwomenages30–65.

Population screening Method

Women <21 No screening

Women 21–29 years Screen with Pap every 3 years

Women 30–65 years HPV and cytology “co-testing” every 5 years (preferred)*

Women >65 No screening following adequate prior normal screening results

NURSE PRACTITIONER &

PHYSICIAN ASSISTANT

SURVEY FINDINGS

The online survey was conducted on behalf of Roche Diagnostics in August 2012 with nurse practitioners and physician assistants.

66%

NEW CERVICAL CANCER SCREENING GUIDELINESWOMEN 30-65 YEARS OLD

50%PAP CYTOLOGY ALONE CAN

MISS APPROXIMATELY

OF CERVICAL PRE-CANCER

AWARE OF NEW GUIDELINES FOR HPV CO-TESTING

14%STILL USE PAP ALONE

BUT

ONLY 1 IN 5 KNOW THE LIMITATIONS OF USING PAP CYLTOLOGY ALONE

How many women will be infected with HPV at some point in their lives?

Q Identify risks and impact associated with HPV genotypes 16 and 18.

Q

WOMEN WILL BE

INFECTEDBY HPV

FOR AN EDUCATIONAL TOOLKIT, VISIT

www.HPV16and18.com/NPPA

ONLY

OF ALL SURVEYEDKNEW THAT THE

CORRECT ANSWER IS 75%+

50%

75%+

OF ALL SURVEYED KNEW GENOTYPES 16 & 18 ARE RESPONSIBLE

FOR APPROXIMATELY

OF ALL CERVICAL CANCER CASES

70%

89%

CERVICAL CANCERAWARENESS

NORMAL CYTOLOGY DOES NOT ALWAYS MEAN

CANCER FREE

*cytology alone every 3 years (acceptable)